There is clear evidence that screening for colorectal cancer (CRC) by stool-based tests is cost-effective
1 and saves lives
2; however, screening remains underused, especially among members of racial/ethnic minority groups and low-income populations.
3 In safety net health care settings and federally qualified health centers (FQHCs) (eTable in the Supplement), in which many medically underserved populations receive care, CRC screening improves when a fecal immunochemical test (FIT) is offered alongside colonoscopy.
4 Additionally, owing to patient preference and limited resources,
5 FIT has become a cornerstone for CRC screening in these settings. Among patients with an abnormal FIT result, the estimated CRC prevalence is 3.4%
6 and a missed or delayed diagnostic colonoscopy is associated with increased CRC mortality.
7,8 Despite these concerns, the proportion of patients with an abnormal FIT result who complete a diagnostic colonoscopy rarely exceeds 50% in most safety net systems and FQHCs.
9-11